FDA grants CymaBay Therapeutics research drug Seladelpar breakthrough therapy

primary bile ductitis (PBC) is a serious and potentially life-threatening liver autoimmune disease characterized by bile siltation and the accumulation of toxic bile acidsThe accompanying inflammation and destruction of the bile ducts in the liver can lead to fibrosis, cirrhosis and liver failurerecently,(http://cymaBay Therapeutics, apharmaceutical(http://, announced that the U.SFDA(http://has awarded the company to researchdrug(http://seladelpar breakthrough therapy, combined with bear deoxyopcus acid (UDCA) treatment for early primary biliary disease (PBC) patients with inadequate relief for UDCA adult patients, or as a single treatment can not be tolerated as a single adult patientexperimental(http://showed a significant improvement in the condition of PBC patients compared to existing therapies based on alkaline phosphatase (AP) reduction The preliminary results of the trial were recently announced at the latest conference of the American Association for The Study of Liver Disease (AASLD) and the International Liver Congress (http:// (EASL)
http:// 　　About Seladelpar
Seladelpar is an efficient, selective peroxidase-activated receptor-activated receptor(PPAR) agonist that is currently in the evaluation phase of the Global Registered Clinical Phase 3 trial for PBC therapy ENHANCE is a 52-week, placebo-controlled global randomized trial that will be conducted in more than 20 countries on 5 continents and will be studied in a group of 240 PBC patients Other ongoing clinical trials include clinical Phase IIb proof-of-concept trials for NASH therapeutic studies 　　About CymaBay CymaBay, a clinical biopharmaceutical company, is committed to developing drugs for liver and other chronic diseases that are still highly medical (http://